ArticleKidney international reports2023
Obinutuzumab in Refractory Phospholipase A2 receptor-Associated Membranous Nephropathy With Severe CKD.
Article in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Efficacy and safety of obinutuzumab as rescue therapy for rituximab-resistant and rituximab-recurrent primary membranous nephropathy: a retrospective cohort study.Open medicine (Warsaw, Poland) · 2026Article
- Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients.Frontiers in immunology · 2026Article
- Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.Clinical kidney journal · 2025Article
- Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.Clinical kidney journal · 2025Review
- Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.Kidney international reports · 2025Article
- Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial.Drug design, development and therapy · 2025Article
- Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study.Frontiers in immunology · 2025Article
- Obinutuzumab in membranous nephropathy: a potential game-changer in treatment.Drugs in context · 2025Review
- Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase AFrontiers in immunology · 2025Article
- Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.Clinical kidney journal · 2024Review
- The role of antibody glycosylation in autoimmune and alloimmune kidney diseases.Nature reviews. Nephrology · 2024Review
- Therapeutic targets in membranous nephropathy: plasma cells and complement.Clinical kidney journal · 2024Review
- Obinutuzumab in Refractory Membranous Nephropathy: A Case Series.Kidney medicine · 2024Article
- Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy.Kidney international reports · 2024Article
- Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia.Frontiers in pharmacology · 2024Article
- Case report: Effective treatment of rituximab-resistant minimal change disease with obinutuzumab in an adult.Frontiers in immunology · 2024Article
- Obinutuzumab as a Promising Treatment for Membranous Nephropathy.Indian journal of nephrologyArticle
- An Updated Review of Membranous Nephropathy.Indian journal of nephrologyReview
- Obinutuzumab in Difficult to Treat Phospholipase A2 Receptor Positive Membranous Nephropathy: Our Experience at a Tertiary Care Center in North India.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.